Drug Discovery World

AUGUST 7, 2024

With over 1,000 different HBV-targeted antibodies in the mixture, GIGA-2339 is unlike any therapy currently in development. We look forward to initiating our trial in late 2024 and showcasing the clinical potential of our recombinant polyclonal antibody platform, starting with HBV.”

Drug Trials 147

Drug Trials FDA Trials Immune Response 147

Drug Discovery World

NOVEMBER 7, 2022

They subsequently applied additional bioinformatic approaches, using advanced computer technologies to identify genetic alterations in a patients’ DNA which may be causing disease but had been overlooked during routine testing. . It can also permit targeted screening of known disease complications and access to drug studies.

Disease 130

Disease Bioinformatics Laboratories DNA 130

Drug Discovery World

JANUARY 17, 2024

This, coupled with a growing understanding of the heterogeneity of cancer as the basis for treatment resistance, tumour evolution and therefore the main source of therapeutic failure, 6 has highlighted the importance of developing personalised therapy. 21 In a recent publication, Silvestri et al.,

DNA 147

DNA Clinical Trials RNA Treatment 147

Drug Discovery World

OCTOBER 6, 2022

Jarret Glasscock , PhD, CEO of Cofactor Genomics explains how diagnostics are emerging as the key to ensuring the right patients get matched to the right therapy, at the right time. . In the cancer space alone over the last five years, clinical trials have increased 500% for new drugs and new drug combinations.

Clinical Trials 130

Clinical Trials Immune Response Therapies Trials 130

Codon

MARCH 14, 2023

For every 5,000 drug compounds tested in mice, five move into human studies. The ALS Therapy Development Institute, located just ten minutes from my home in Cambridge, once tested more than 100 potential drugs to slow ALS progression in mice, all of which had been reported to be helpful in other studies. Nobody really knows why.

DNA 52

DNA Laboratories Animal Testing Engineering 52